Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Florbetaben PET in Amyloid Cerebral Angiopathy
NCT02664571Withdrawn
- Sponsor
- CHU Nîmes
- Start
- Jul 2020
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of florbetaben in cerebral amyloid angiopathy (CAA) and Alzheimer's disease (AD) (4 arms), sponsored by CHU Nîmes. Primary endpoint: Standardized Uptake Value Ratio at Day 0. Planned start Jul 2020; status: withdrawn.
02
Drugs
florbetaben
03
Conditions
cerebral amyloid angiopathy (CAA)Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02664571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02664571.